^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HNRNPD overexpression

    i
    Other names: HNRNPD, Heterogeneous Nuclear Ribonucleoprotein D, HNRPD, AUF1, AU-Rich Element RNA Binding Protein 1, 37kDa, Heterogeneous Nuclear Ribonucleoprotein D0, HnRNP D0, Heterogeneous Nuclear Ribonucleoprotein D (AU-Rich Element RNA-Binding Protein 1, 37kD), AU-Rich Element RNA-Binding Protein 1, ARE-Binding Protein AUFI, Type A, HnRNPD0, AUF1A, P37
    Entrez ID:
    3184
    3ms
    Impact of heterogeneous nuclear ribonucleoprotein A/B subtype overexpression on the expression of cancer stem cell markers CD133 and CD44 and cellular proliferation capacity. (PubMed, Cell Mol Biol (Noisy-le-grand))
    The invasive, migratory, and proliferative abilities of cells in group E were notably enhanced, and tumor growth was observably faster versus group C. OP of hnRNPA1 was closely associated with the activation of Wnt/β-catenin signaling and promoted the proliferation and invasive capacity of tumor cells. hnRNPA1 played an imperative role in intestinal cancer stem cells.
    Journal • Cancer stem
    |
    CCND1 (Cyclin D1) • HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B)
    |
    CD133 expression • HNRNPD overexpression
    12ms
    HnRNPAB is an independent prognostic factor in non‑small cell lung cancer and is involved in cell proliferation and metastasis. (PubMed, Oncol Lett)
    Mechanistically, the bioinformatics analysis and RT-qPCR verification demonstrated that hnRNPAB knockdown led to a significant expression change of genes associated with tumorigenesis. In conclusion, the present study indicated that hnRNPAB played an important role in the malignant transformation of NSCLC, supporting the significance of hnRNPAB as a novel potential therapeutic target for the early diagnosis and prognosis of NSCLC.
    Journal
    |
    HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B)
    |
    HNRNPD overexpression